Systemic antifungal therapy

Dermatologic Clinics

Volumn 19, Issue 1, 2001, Pages 35-52

  Moossavi, Meena ^a   Bagheri, Bita ^a   Scher, Richard K ^a  

^a Department of Dermatology ^*

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; MYCOSIS; ONYCHOMYCOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TINEA CAPITIS; TINEA VERSICOLOR;

EID: 0035172226     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70228-X     Document Type: Article

References (234)

1. Investigation of terbinafine as a CYP2D6 inhibitor in vivo
2. Oral terbinafine: A new antifungal agent
3. Ciclosporin A and griseofulvin: Another drug interaction
4. Fluconazole-induced thrombocytopenia
5. Adverse drug reactions of the new oral antifungal agents - Terbinafine, fluconazole, and itraconazole
6. Induction of fluconazole metabolism by rifampin: In vivo study in humans
7. Intermittent fluconazole dosing in patients with onychomycosis: Results of a pilot study
8. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity
9. Effect of particle size on blood griseofulvin levels in man
10. Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection
11. Ketoconazole and fluconazole drug interactions
12. Terbinafine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses
13. Antifungal agents
14. Ketoconazole-induced fulminant hepatitis
15. Pharmacology of the allylamines
16. Report of successful desensitization to itraconazole
17. Warfarinfluconazole: II. A metabolically-based drug interaction: In vitro studies
18. Treatment of oral candidosis with itraconazole: A review
19. Azole antifungal agents
20. Itraconazole pharmacokinetics in patients with renal dysfunction
21. Hepatitis attributed to the use of terbinafine
22. Fixed drug eruption induced by griseofulvim
23. Pharmacokinetics and tissue penetration of fluconazole in humans
24. A review of the pharmacokinetics of fluconazole (UK-49, 858) in laboratory animals and man
25. An epidemic of infection with Trichophyton tonsurans revealed in a 20 year survey of fungal infections in Chicago
26. Ketoconazole hepatotoxicity in a patient treated for environmental illness and systemic candidiasis
27. Fluconazole-induced symptomatic phenytoin toxicity
28. Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: A double-blind, randomized pharmacokinetic and safety study
29. Itraconazole in the treatment of human mycoses: Review of three years of clinical experience
30. In vitro activity of terbinafine
31. Itraconazole in antifungal therapy
32. Stability of fluconazole and amino acids in parenteral nutrient solutions
33. Human pharmacology of griseofulvin: The effect of fat intake on gastrointestinal absorption
34. Influence of food on the pharmacokinetics of ketoconazole
35. Clinical pharmacokinetics of ketoconazole
36. Data on file
37. Safety aspects of itraconazole therapy in vaginal candidiasis, dermatomycosis and onychomycosis: A review
38. Clinical pharmacokinetics of fluconazole
39. Antifungal pulse therapy for onychomycosis
40. Current therapy of dermatophytosis
41. A comparative double-blind study of terbinafine (lamisil) and griseofulvin in tinea corporis and tinea cruris
42. Clinical applications of ketoconazole in prostatic cancer
43. Ketoconazole
44. Ketoconazole and cyclosporin
45. Diflucan package insert prescribing information
46. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial
47. Drug topics red book
48. Cisapride labelling change
49. Acute generalized exanthematous pustulosis induced by terbinafine
50. Determination of terbinafine in nail samples during systemic treatment for onychomycosis
51. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective
52. Tinea capitis
53. Once-weekly fluconazole in the treatment of onychomycosis: Introduction
54. Treatment of tinea capitis: Beyond grise Mulvin
55. Tinea capitis
56. Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis
57. Griseofulvin levels in stratum corneum
58. Tinea versicolor: Treatment and prophylaxis with monthly administration of ketoconazole
59. Griseofulvin and ketoconazole: A review with special emphasis on dermatology
60. Levels of terbinafine in plasma, stratum corneum, dermisepidermis (without stratum corneum), sebum, hair, nails during and after 250 mg terbinafine orally once per day for four weeks
61. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum, and eccrine sweat
62. One-week therapy with oral terbinafine in cases of tinea cruris/corporis
63. Pharmacokinetics of terbinafine in the nail
64. Global overview of lamisil
65. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails
66. The response of seborrheic dermatitis to ketoconazole
67. Pityrosporum folliculitis and ketoconazole
68. Fluconazole-induced jaundice
69. Pediatric antifungal therapy
70. Single dose therapy of tinea capitis
71. Overview of medically important azole derivatives
72. Fluconazole-nortriptyline drug interaction
73. Treatment of kerion with fluconazole
74. Experimental ringworm in guinea pigs: Oral treatment with griseofulvin
75. Pharmacokinetic drug interactions with antimicrobial agents
76. Effect of feeding on bioavailability of griseofulvin in children
77. Griseofulvin for eosinophilic fasciitis
78. Black piedra: The first case treated with terbinafine (lamisil)
79. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses
80. Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential insuperficial and systemic mycoses
81. New antifungal agents
82. Ketoconazole therapy for fungal urinary tract infections
83. Antimitotic action of griseofulvin does not involve disruption of microtubules
84. Griseofulvin inhibits fungal mitosis
85. Drug interactions with itraconazole, fluconazole, and terbinafine and their management
86. Antifungal agents: An overview: Part I
87. Antifungal agents: An overview: Part II
88. Oral antifungal agents for onychomycosis
89. Stevens-Johnson syndrome after fluconazole
90. Pharmacokinetic evaluation of fluconazole in plasma, epidermis and blister fluid
91. Fluconazole levels in human epidermis and blister fluid
92. Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: A multicentre trial
93. The use of itraconazole in onychomycosis
94. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea captis
95. Orally administered ketoconazole: Route of delivery to stratum corneum
96. Drugs recently released in Belgium
97. Onychomycosis: Agents of choice
98. A comparative double-blind study of ketoconazole and griseofulvin in dermatophytosis
99. Itraconazole in the management of chronic dermatophytosis
100. Tinea capitis caused by Trichophyton tonsurams
101. Pharmacokinetic properties
102. Antimycotic azoles: Synthetic and antifungal properties of a series of novel triazol-3-ones
103. Fluconazole: A significant advance in the management of human fungal disease
104. Development and evaluation of antifungal agents
105. Pharmacokinetics of oral antifungals and their clinical implications
106. Plasma levels and urinary excretion of ketoconazole following oral administration to patients with severe renal insufficiency
107. Itraconazole-induced acute generalized exanthemic pustulosis
108. Endocrine effects of high-dose ketoconazole therapy in advanced prostate cancer
109. Stratum corneum kinetics of topical terbinafine: Fungicidal concentrations with short course therapy
110. Ketoconazole in management of precocious puberty not responsive to LHRH-analogue therapy
111. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans
112. Phenytoin toxicity induced by fluconazole
113. Fatal acute hepatic necrosis due to fluconazole
114. Hepatic reactions during ketoconazole treatment
115. Clinical pharmacokinetics of terbinafine (lamisil)
116. Pityriasis versicolor with ketoconazole
117. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis
118. Thrombocytopenia caused by fluconazole
119. Systematic antifungal agents used to treat onychomycosis
120. Oral antifungal drug interactions
121. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: A 6-week pilot study
122. Inhibition of terfenadine in humans
123. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation
124. Gastrointestinal absorption of griseofulvin: II. Influence of particle size in man
125. Current status of the identification and management of tinea capitis
126. Warfarin-fluconazole: III. A rational approach to management of a metabolically-based drug interaction
127. Warfarin-fluconazole: I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies
128. Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis: A review of the literature
129. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS)
130. Itraconazole pharmacokinetics in the female genital tract: Plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole
131. Hepatic injury associated with itraconazole
132. The clinical pharmacology of fluconazole
133. Congenital malformations in an infant born to a woman treated with fluconazole
134. Itraconazole in the treatment of tinea capitis
135. Recent developments in antifungal therapy
136. Response of the cutaneous lesions of Reiter's syndrome to ketoconazole
137. How orally administered terbinafine reaches the stratum corneum
138. Investigation of the pharmacokinetics of oral and topical terbinafine
139. Hepatic injury associated with ketoconazole therapy: Analysis of 33 cases
140. Absorption, distribution, metabolism and excretion of griseofullvin in man and animals
141. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes
142. Fluconazole-cyclosporine interaction: A dose-dependent effect?
143. Itraconazole versus griseofulvin in the treatment of tinea capitis: A double-blind randomized study in children
144. Systematically administered antifungal agents
145. Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin
146. The discovery and mode of action of fluconazole
147. Ageusia caused by terbinafine
148. Dermatophytosis of the feet
149. Fluconazole moderately increases midazolam effects on performance
150. Biochemical studies on the metabolism of griseofulvin
151. Kinetics and spectrum of activity of oral antifungals: The therapeutic implications
152. Thrombocytopenia caused by fluconazole therapy
153. Griseofulvin: Immunosuppressive action
154. Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin
155. Therapy with fluconazole for tinea capitis, tinea cruris, and tinea pedis
156. A third case of photo-allergic reaction to Sporanox (itraconazole)
157. In vivo and in vitro inhibition of hepatic microsomal drug metabolism by ketoconazole
158. Terbinafine and fixed drug eruption
159. Short duration terbinafine therapy penetrates diseased nail via the ventral nail bed and is effective in onychomycosis
160. The route of rapid access of drugs to the distal nail plate
161. Terbinafine-induced lupus erythematosus
162. Itraconazole: Pharmacokinetics and indications
163. A fluconazole/amitriptyline drug interaction in three adult males
164. Terbinafine in onychomycosis with involvement by non-dermatophyte fungi
165. Single dose and intermittent griseofulvin regimens in the treatment of tinea capitis in Kenya
166. Spectrum of orally active antifungals
167. New therapies for onychomycosis
168. Loss of taste and terbinafine
169. 6Cl a metabolic product of penicillium griseofulvin
170. Alopecia associated with fluconazole therapy
171. Serum sickness-like reaction to itraconazole
172. Adverse drug reactions to systemic antifungals: Prevention and management
173. Ketoconazole blocks testosterone synthesis
174. Ketoconazole blocks adrenal steroid synthesis
175. The rise and fall of flourescent tinea capitis
176. Effects of griseofulvin on the morphology, growth and metabolism of fibroblasts in culture
177. Inhibited proliferation of human scleroderma skin fibroblasts and rheumatoid synovial cells with griseofulvin in vitro
178. Propulsid package insert prescribing information
179. Fluconazole-induced congenital anomalies in three infants
180. Tinea versicolor: Treatment and prophylaxis with monthly administration of ketoconazole
181. Oral ketoconazole in cutaneous fungal infections
182. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes
183. Safety of fluconazole in women taking oral hypoglycemic agents
184. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition
185. Inhibitions of squalene epoxidase by allylamine antimycotic compounds: A comparative study of the fungal and mammalian enzymes
186. Allylamine antifungal drugs
187. Stevens-Johnson syndrome after terbinafine
188. Azole antifungal agents: Emphasis on new triazoles
189. Antimicrobial agents
190. Itraconazole in common dermatophyte infections of the skin: Fixed treatment schedules
191. Pharmacokinetics of itraconazole following oral administration to normal volunteers
192. Treatment of chronic moccasin-type tinea pedis with terbinafine: A double-blind placebo-controlled trial
193. Pharmacokinetic optimisation of oral antifungal therapy
194. Oral antifungals
195. Successful treatment of Aspergillus flavus onychomycosis with oral itraconazole
196. Once weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail
197. Preclinical characteristics of allylamines
198. Treatment of Candida nail infection with terbimafine
199. Seldane package insert prescribing information
200. Are laboratory studies necessary for griseofulvin therapy?
201. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis
202. Fluconazole for the treatment of tinea capitis in children
203. The use of ketoconazole as an inhibitor of steroid production
204. Anti-inflammatory properties of griseofulvin
205. Sporanox package insert prescribing information
206. Terbinafine: Initial clinical results
207. Ketoconazole-associated hepatic injury: A clinicopathological study of 55 cases
208. Mechanisms of action of the antimycotic imidazoles
209. Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis
210. Oral terbinafine and erythema multiforme
211. Ketoconazole therapy for advanced prostate cancer
212. Interaction of azoles with rifampin, phenytoin, and carbamazepine: In vitro and clinical observations
213. Adverse events associated with itraconazole in 189 patients on chronic therapy
214. Itraconazole: Pharmacologic studies in animals and humans
215. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis
216. Nortriptyline intoxication induced by terbinafine
217. Interactions between oral contraceptives and griseofulvin
218. Acute hepatitis related to the ingestion of terbinafine
219. Ketoconazole: Mechanisms of action, spectrum of activity, pharmacodynamics, drug interactions, adverse reactions, and therapeutic use
220. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism
221. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases
222. Severe erythema annulare centrifugum-like psoriatic drug eruption induced by terbinafine
223. Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenged
224. Toxic epidermal necrolysis induced by terbinafine in a patient on long-term anti-epileptics
225. New therapeutic concepts in onychomycosis
226. Oral treatment of ringworm with griseofulvin
227. Ketoconazole for prostate cancer
228. Pityrosporum, ketoconazole, and seborrheic dermatotitis
229. Pityriasis versicolor with ketoconazole
230. Fluconazole (Diflucan: A review)
231. Itraconazole: A new triazole antifungal agent